Results 21 to 30 of about 3,216,105 (293)

Patients With Rheumatoid Arthritis With an Inadequate Response to Disease‐Modifying Antirheumatic Drugs at a Higher Risk of Acute Coronary Syndrome

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2021
Background Cardiovascular disease is the most common cause of death in patients with rheumatoid arthritis. It is believed that using disease‐modifying antirheumatic drugs (DMARDs) to control inflammation can reduce the risk of cardiovascular disease.
Chung‐Yuan Hsu, Yu‐Jih Su, Jia‐Feng Chen, Chi‐Chin Sun, Tien‐Tsai Cheng, Tzu‐Hsien Tsai, Shang‐Hong Lin, Cheng‐Chieh Chang, Tien‐Hsing Chen   +8 more
doaj   +1 more source

Baseline use of hydroxychloroquine or immunosuppressive drugs and the risk of coronavirus disease 2019 [PDF]

The Korean Journal of Internal Medicine, 2022
Background/Aims The preventive role of hydroxychloroquine (HCQ) on coronavirus disease 2019 (COVID-19) remains unclear. The aim of this study was to examine the effects of HCQ and other immunosuppressive drugs on the incidence of COVID-19.
Ji-Won Kim, Sang Gyu Kwak, Hwajeong Lee, Seong-Kyu Kim, Jung-Yoon Choe, Sung-Hoon Park   +5 more
doaj   +1 more source

Coronavirus disease 2019 in patients with rheumatic immune-mediated diseases in a single University Hospital, matched case-control study and literature review

Frontiers in Medicine, 2022
BackgroundCOVID-19 may present different degrees of severity. Viral infections in patients with rheumatic inflammatory diseases (R-IMID) trend to present more severe disease.
David Martínez-López, Ivan Ferraz-Amaro, Diana Prieto-Peña, Lara Sánchez-Bilbao, Alba Herrero-Morant, Carmen Álvarez-Reguera, Fabricio Benavides-Villanueva, Cristina Corrales-Selaya, Martín Trigueros-Vázquez, Miguel Ángel González-Gay, Ricardo Blanco   +10 more
doaj   +1 more source

Comparative evaluation of efficacy, pharmacodynamics, and safety of Hetero’s adalimumab (Mabura®, Hetero Biopharma Ltd.) and reference adalimumab (Humira®, Abbvie Inc.) in patients with active rheumatoid arthritis on concomitant methotrexate therapy

BMC Rheumatology, 2020
Background Our study aimed to compare efficacy and safety of Hetero’s adalimumab (Mabura®, Hetero Biopharma Limited) versus reference adalimumab (Humira®, Abbvie Inc.) in Indian patients with active rheumatoid arthritis (RA) concomitant on methotrexate ...
Shubhadeep Sinha, Biswadip Ghosh, Syamasis Bandyopadhyay, Firdaus Fatima, Vamsi Krishna Bandi, Pankaj Thakur, Bala Reddy, Sreenivasa Chary, Leela Talluri, Ajay Gupta, Amit Ramchandra Kale, Anil Kumar Gupta, Ashok Kumar P, Diwakar Reddy, Younus Mohammed, Soma Shekar, Sudheer T, Vijay G. Goni, Vishnu Sharma, Vishwanath Yeligod   +19 more
doaj   +1 more source

Aliskiren, tadalafil, and cinnamaldehyde alleviate joint destruction biomarkers; MMP-3 and RANKL; in complete Freund's adjuvant arthritis model: Downregulation of IL-6/JAK2/STAT3 signaling pathway

Saudi Pharmaceutical Journal, 2020
Rheumatoid arthritis (RA) is an autoimmune inflammatory disease, which is accompanied by progressive joint damage and disability. The intolerability of conventional antirheumatic drugs by some patients necessitates the search for effective antirheumatic ...
Amany A. Azouz, Esraa Saleh, Ali A. Abo-Saif   +2 more
doaj   +1 more source

Updated American College of Rheumatology/American Association of Hip and Knee Surgeons guideline for the perioperative management of antirheumatic medication in patients with rheumatic diseases undergoing elective total hip or total knee arthroplasty 2022

Научно-практическая ревматология, 2023
The article presents updated guidelines developed by the American College of Rheumatology and the American Association of Hip and Knee Surgeons on the perioperative treatment of patients with rheumatoid arthritis, ankylosing spondylitis, psoriatic ...
V. N. Amirjanova, M. A. Makarov, A. E. Karateev, A. E. Khramov, S. V. Maglevaniy, A. V. Rozov, V. A. Nesterenko, E. L. Nasonov   +7 more
doaj   +1 more source

Efficacy and safety of ixekizumab through 52 weeks in two phase 3, randomised, controlled clinical trials in patients with active radiographic axial spondyloarthritis (COAST-V and COAST-W). [PDF]

, 2020
OBJECTIVES: To investigate the efficacy and safety of ixekizumab for up to 52 weeks in two phase 3 studies of patients with active radiographic axial spondyloarthritis (r-axSpA) who were biological disease-modifying antirheumatic drug (bDMARD)-naive ...
Baraliakos, X., Bertram, C.C., Bosch, F. van den, Carlier, H., COAST-V Study Grp, COAST-W Study Grp, Deodhar, A., Dougados, M., Ermann, J., Gallo, G., Gensler, L.S., Heijde, D. van der, Landewe, R., Li, X.Q., Maksymowych, W.P., Sieper, J., Tomita, T., Walsh, J.A., Wei, J.C.C., Zhao, F.Y.   +19 more
core   +3 more sources

Recent advances: rheumatology [PDF]

, 2000
No abstract ...
Madhok, R., Kerr, H., Capell, H.A.
core   +6 more sources

A case of essential thrombocythemia and ankylosing spondylitis treated with a combination of anagrelide, disease-modifying antirheumatic drugs, and etanercept [PDF]

Srpski Arhiv za Celokupno Lekarstvo, 2016
Introduction. A high platelet count, or thrombocytosis, is either a reactive process or a result of a myeloproliferative disorder. Ankylosing spondylitis is a chronic inflammatory rheumatic disease affecting the spine and sometimes peripheral ...
Zeremski Vanja, Savić Aleksandar, Ilić Tatjana, Milošević Ivana, Maksimović Marina, Vučković Biljana   +5 more
doaj   +1 more source

The use of combinations of disease‐modifying antirheumatic agents in rheumatoid arthritis [PDF]

Arthritis & Rheumatism, 1990
Harold E. Paulus
openaire   +4 more sources